AR079164A1 - Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. - Google Patents
Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.Info
- Publication number
- AR079164A1 AR079164A1 ARP100104362A ARP100104362A AR079164A1 AR 079164 A1 AR079164 A1 AR 079164A1 AR P100104362 A ARP100104362 A AR P100104362A AR P100104362 A ARP100104362 A AR P100104362A AR 079164 A1 AR079164 A1 AR 079164A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- alkoxy
- alkyl
- substituents selected
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 14
- 125000001424 substituent group Chemical group 0.000 abstract 14
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000003277 amino group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- -1 cyclic amine Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005111 carboxyalkoxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicacion 1: Un compuesto representado por la formula (1) o una de sus sales farmacéuticamente aceptables caracterizado porque R1 es un átomo de hidrogeno, un grupo hidroxi, o un grupo alcoxi C1-6 opcionalmente sustituido con grupos arilo C6-10; R2 y R3 son iguales o diferentes y cada uno es un átomo de hidrogeno, o un grupo alquilo C1-6 opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi y un grupo alcoxi C1-6; y R4 es un grupo representado por -C(=O)-N(R5)(R6) o -N(R7)-C(=O)-(R8)que se une a la posicion 5 o la posicion 6 del anillo indol en donde R5 es un átomo de hidrogeno, o un grupo alquilo C1-6, y R6 es un átomo de hidrogeno, un grupo alquilo C1-6 opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi, un grupo alcoxi C1-6, un grupo carboxi, un grupo alcoxi C1-6-carbonilo, un grupo arilo C6-10, (f) un grupo aril C6-10-oxi, un grupo amino opcionalmente mono- o disustituido con grupos alquilo C1-6, un grupo heterocíclico insaturado de 5 o 6 miembros opcionalmente sustituido con grupos alquilo C1-6 y un grupo heterocíclico saturado de 5 o 6 miembros, alcoxi C1-6, arilo C6-10, o (5) un grupo heterocíclico insaturado de 5 o 6 miembros opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de hidroxi y alcoxi C1-6 o R5 y R6 forman, junto con el átomo de nitrogeno al que están unidos, una amina cíclica de 5 o 6 miembros (dicha amina cíclica está opcionalmente condensada con heterociclo insaturado de 5 o 6 miembros) opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi, alquilo C1-6, alcoxi C1-6 y alcoxi C1-6-carbonilo; R7 es un átomo de hidrogeno, o alquilo C1-6 opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi, alcoxi C1-6 y un grupo amino opcionalmente mono- o disustituido con grupos alquilo C1-6, y R8 es un grupo alquilo C1-6 opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi, alcoxi C1-6 opcionalmente sustituido con grupos arilo C6-10, un grupo cicloalquilo C3-6 sustituido con grupos alcoxi C1-6, un grupo arilo C6-10, un grupo heterocíclico insaturado de 5 o 6 miembros opcionalmente sustituido con grupos oxo, un grupo heterocíclico saturado de 5 a 8 miembros opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi, un grupo alquilo C1-6 opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi y un grupo alcoxi C1-6, alcoxi C1-6 y un grupo oxo, un grupo cicloalquil C3-6-oxi, un grupo aril C6-10-oxi, un grupo heterocicliloxi insaturado de 5 o 6 miembros, un grupo heterocicliloxi saturado de 5 o 6 miembros y un grupo amino opcionalmente mono- o disustituido con sustituyentes seleccionados de un grupo alquilo C1-6 opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi, un grupo carboxi y un grupo carboxi-alcoxi C1-6, un grupo alquil C1-6-carbonilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi y un grupo alcoxi C1-6, un grupo alcoxi C1-6-carbonilo opcionalmente sustituido con grupos arilo C6-10, y un grupo cicloalquil C3-6-carbonilo opcionalmente sustituido con grupos alcoxi C1-6, un grupo alcoxi C1-6 opcionalmente sustituido con grupos arilo C6-10, un grupo cicloalquilo C3-6 opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un grupo hidroxi y un grupo alcoxi C1-6, arilo C6-10 opcionalmente sustituido con grupos alquilo C1-6 opcionalmente sustituido con 1 a 3 átomos de halogeno, un grupo amino opcionalmente mono- o disustituido con grupos alquilo C1-6 opcionalmente sustituido con grupos arilo C6-10, un grupo heterocíclico insaturado de 5 o 6 miembros opcionalmente sustituido con grupos alquilo C1-6, un grupo heterocíclico saturado de 5 o 6 miembros opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de alquilo C1-6, un grupo alquil C1-6-carbonilo y un grupo oxo, un grupo cicloalquil C3-6-oxi, o un grupo aril C6-10-carbonilo o R7 y R8 forman, junto con el átomo de nitrogeno y el átomo de carbono al que están unidos, una amina cíclica de 5 o 6 miembros sustituidos con un grupo oxo y también opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados de un grupo hidroxi, un grupo alquilo C1-6 opcionalmente sustituido con grupos hidroxi, alcoxi C1-6 y cicloalquilo C3-6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009268040 | 2009-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079164A1 true AR079164A1 (es) | 2011-12-28 |
Family
ID=44066507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104362A AR079164A1 (es) | 2009-11-25 | 2010-11-25 | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US8299070B2 (es) |
| EP (3) | EP2505586B1 (es) |
| JP (6) | JP5734628B2 (es) |
| KR (1) | KR101766502B1 (es) |
| CN (1) | CN102712624B (es) |
| AR (1) | AR079164A1 (es) |
| AU (1) | AU2010323579C1 (es) |
| BR (1) | BR112012012529B1 (es) |
| CA (1) | CA2781660C (es) |
| CL (1) | CL2012001328A1 (es) |
| CO (1) | CO6541645A2 (es) |
| CY (1) | CY1117559T1 (es) |
| DK (1) | DK2505586T3 (es) |
| ES (1) | ES2572935T3 (es) |
| HR (1) | HRP20160579T1 (es) |
| HU (1) | HUE028016T2 (es) |
| IL (1) | IL220009A (es) |
| ME (1) | ME02447B (es) |
| MX (1) | MX2012006017A (es) |
| MY (1) | MY161095A (es) |
| NZ (1) | NZ600840A (es) |
| PE (1) | PE20121358A1 (es) |
| PH (1) | PH12012501021A1 (es) |
| PL (1) | PL2505586T3 (es) |
| PT (1) | PT2505586E (es) |
| RS (1) | RS54910B1 (es) |
| RU (1) | RU2556216C2 (es) |
| SI (1) | SI2505586T1 (es) |
| SM (1) | SMT201600258B (es) |
| TW (1) | TWI491591B (es) |
| WO (1) | WO2011065402A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| US20120087915A1 (en) | 2010-06-03 | 2012-04-12 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
| AU2013337663A1 (en) | 2012-11-02 | 2015-06-11 | Pharmacyclics Llc | TEC family kinase inhibitor adjuvant therapy |
| CN103804364A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| CN103804361A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804291A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800328A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800337A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800340A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
| CN103804351A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804363A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804302A (zh) * | 2012-11-14 | 2014-05-21 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103804272A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| TW201625605A (zh) * | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| WO2016002918A1 (ja) * | 2014-07-04 | 2016-01-07 | 日本たばこ産業株式会社 | インドール化合物の製造方法 |
| WO2016010108A1 (ja) * | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| CN104356086A (zh) * | 2014-11-28 | 2015-02-18 | 湖南科技大学 | 一种适于工业生产3-吗啉酮的制备方法 |
| DK3801546T3 (da) * | 2018-05-25 | 2024-08-12 | Japan Tobacco Inc | Indolforbindelse til behandling af interstitiel cystitis |
| US12458646B2 (en) * | 2018-05-25 | 2025-11-04 | Japan Tobacco Inc. | Therapeutic or preventing agent for multiple sclerosis including indole compound |
| EP3804727B1 (en) * | 2018-05-25 | 2023-10-11 | Japan Tobacco Inc. | Indol-containing compound for use in the treatment of the nephrotic syndrome |
| JP2023507138A (ja) | 2019-12-20 | 2023-02-21 | ファイザー・インク | ベンゾイミダゾール誘導体 |
| KR102270026B1 (ko) * | 2020-01-31 | 2021-06-28 | 현대약품 주식회사 | (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법 |
| CA3205023A1 (en) * | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease |
| US20240132477A1 (en) * | 2020-12-15 | 2024-04-25 | Pfizer Inc. | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease |
| JP2024517831A (ja) * | 2021-05-03 | 2024-04-23 | ニューリックス セラピューティクス，インコーポレイテッド | Ｉｔｋを阻害又は分解するための化合物、それを含む組成物、それらの作製方法及びそれらの使用方法 |
| WO2022235698A1 (en) * | 2021-05-03 | 2022-11-10 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| TW202315618A (zh) * | 2021-06-11 | 2023-04-16 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物 |
| AU2022370351A1 (en) * | 2021-10-19 | 2024-05-02 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway |
| KR20250166329A (ko) * | 2023-04-13 | 2025-11-27 | 다나틀라스 파마슈티컬즈 씨오., 엘티디. | 티아디아졸론 유도체 및 이의 조성물과 응용 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US953411A (en) * | 1908-09-02 | 1910-03-29 | Erastus De Moulin | Trick weight-lifting machine. |
| BR0213562A (pt) * | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| ES2262996T3 (es) * | 2002-01-07 | 2006-12-01 | Eisai Co., Ltd. | Deazapurinas y sus usos. |
| JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| FR2854159B1 (fr) * | 2003-04-25 | 2008-01-11 | Aventis Pharma Sa | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| TWI352705B (en) * | 2003-09-08 | 2011-11-21 | Aventis Pharma Inc | Thienopyrazoles |
| EP1880993A4 (en) * | 2005-04-19 | 2009-12-30 | Kyowa Hakko Kirin Co Ltd | NITROGENIC HETEROCYCLIC COMPOUND |
| US20080293714A1 (en) * | 2005-12-20 | 2008-11-27 | Joerg Martin Bentzien | Tec Kinase Inhibitors |
| GB0602178D0 (en) * | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| MX2008012482A (es) * | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| EP2865381A1 (en) * | 2006-05-18 | 2015-04-29 | Pharmacyclics, Inc. | ITK inhibitors for treating blood cell malignancies |
| JPWO2008047831A1 (ja) * | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| WO2008058402A1 (en) | 2006-11-17 | 2008-05-22 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| JP2009268040A (ja) | 2008-04-23 | 2009-11-12 | Teruhiko Daiho | ループアンテナ装置 |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
-
2010
- 2010-11-24 US US12/954,438 patent/US8299070B2/en active Active
- 2010-11-25 TW TW099140715A patent/TWI491591B/zh active
- 2010-11-25 EP EP10833248.7A patent/EP2505586B1/en active Active
- 2010-11-25 CN CN201080062299.3A patent/CN102712624B/zh active Active
- 2010-11-25 MX MX2012006017A patent/MX2012006017A/es active IP Right Grant
- 2010-11-25 PL PL10833248.7T patent/PL2505586T3/pl unknown
- 2010-11-25 BR BR112012012529-0A patent/BR112012012529B1/pt active IP Right Grant
- 2010-11-25 HU HUE10833248A patent/HUE028016T2/en unknown
- 2010-11-25 AU AU2010323579A patent/AU2010323579C1/en active Active
- 2010-11-25 SI SI201031188A patent/SI2505586T1/sl unknown
- 2010-11-25 KR KR1020127016311A patent/KR101766502B1/ko active Active
- 2010-11-25 PE PE2012000713A patent/PE20121358A1/es active IP Right Grant
- 2010-11-25 DK DK10833248.7T patent/DK2505586T3/en active
- 2010-11-25 NZ NZ600840A patent/NZ600840A/en unknown
- 2010-11-25 ES ES10833248.7T patent/ES2572935T3/es active Active
- 2010-11-25 CA CA2781660A patent/CA2781660C/en active Active
- 2010-11-25 AR ARP100104362A patent/AR079164A1/es active IP Right Grant
- 2010-11-25 HR HRP20160579TT patent/HRP20160579T1/hr unknown
- 2010-11-25 EP EP16158053.5A patent/EP3059234A1/en not_active Withdrawn
- 2010-11-25 JP JP2010262058A patent/JP5734628B2/ja active Active
- 2010-11-25 RS RS20160385A patent/RS54910B1/sr unknown
- 2010-11-25 PT PT108332487T patent/PT2505586E/pt unknown
- 2010-11-25 PH PH1/2012/501021A patent/PH12012501021A1/en unknown
- 2010-11-25 MY MYPI2012002292A patent/MY161095A/en unknown
- 2010-11-25 ME MEP-2016-107A patent/ME02447B/me unknown
- 2010-11-25 WO PCT/JP2010/070988 patent/WO2011065402A1/ja not_active Ceased
- 2010-11-25 RU RU2012126129/04A patent/RU2556216C2/ru active
- 2010-11-25 EP EP20189306.2A patent/EP3766877A1/en not_active Withdrawn
-
2012
- 2012-05-23 CL CL2012001328A patent/CL2012001328A1/es unknown
- 2012-05-24 IL IL220009A patent/IL220009A/en active IP Right Grant
- 2012-06-22 CO CO12105036A patent/CO6541645A2/es active IP Right Grant
- 2012-09-26 US US13/627,047 patent/US20130116240A1/en not_active Abandoned
-
2015
- 2015-04-15 JP JP2015083457A patent/JP2015172051A/ja not_active Ceased
-
2016
- 2016-05-26 CY CY20161100462T patent/CY1117559T1/el unknown
- 2016-08-03 SM SM201600258T patent/SMT201600258B/it unknown
- 2016-10-20 JP JP2016205949A patent/JP2017039761A/ja not_active Ceased
- 2016-10-28 US US15/337,583 patent/US20170267662A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/869,250 patent/US20180362506A1/en not_active Abandoned
- 2018-06-13 JP JP2018112445A patent/JP2018158935A/ja active Pending
-
2019
- 2019-09-19 US US16/575,724 patent/US20200255408A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020017065A patent/JP2020079276A/ja not_active Ceased
- 2020-09-23 US US17/029,642 patent/US20210284627A1/en not_active Abandoned
-
2021
- 2021-03-03 JP JP2021033138A patent/JP2021091718A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| PE20190446A1 (es) | Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4 | |
| PE20240687A1 (es) | Compuestos de indazol como inhibidores de cinasas | |
| MX2020000261A (es) | Nuevos compuestos. | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| ECSP11011200A (es) | Derivados de oxadiazale como agonista de los receptores s1p1 | |
| AR101986A1 (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR076235A1 (es) | Compuestos organicos y sus usos | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR092288A1 (es) | Ligandos del receptor ep1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |